Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Group-Based Contingency Management for Substance Abuse Treatment - 1

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
UConn Health Identifier:
First received: November 3, 2005
Last updated: November 17, 2011
Last verified: November 2011
The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.

Condition Intervention
Substance Abuse
Behavioral: Contingency management

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Group-Based Contingency Management for Substance Abuse Treatment

Further study details as provided by UConn Health:

Primary Outcome Measures:
  • Drug use [ Time Frame: baseline and at each follow-up ] [ Designated as safety issue: No ]
  • Retention [ Time Frame: each follow-up ] [ Designated as safety issue: No ]

Enrollment: 312
Study Start Date: May 2005
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Contingency management
    Receive rewards (prizes) abstinence and attendance

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • age > 18 years
  • current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence
  • willing to provide breath and urine samples for 12 weeks
  • English speaking
  • willing to sign informed consent

Exclusion criteria:

  • serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)
  • dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975)
  • in recovery from pathological gambling
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00249717

United States, Connecticut
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Sponsors and Collaborators
UConn Health
National Institute on Drug Abuse (NIDA)
Principal Investigator: Nancy Petry, Ph.D. UConn Health
  More Information

Responsible Party: UConn Health Identifier: NCT00249717     History of Changes
Other Study ID Numbers: NIDA-18883-1  R01DA018883 
Study First Received: November 3, 2005
Last Updated: November 17, 2011
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by UConn Health:
Contingency management
Substance abuse treatment

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on October 21, 2016